Interestingly, another study, using TRO in combination with cisplatin in A549 and H522 non-small-cell lung cancer cells, found synergistic effects when TRO treatment followed cisplatin treatment but not vice versa, suggesting that the beneficial effects of PPARγ activation might depend on the sequence of drug administration [33]. This evidence concerns the gene PPARG and non-small cell lung carcinoma.